Cover Image

Partnerships, Licensing, Investments and M&A Deals and Trends for May 2015 in Pharmaceuticals

GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for May 2015 in Pharmaceuticals" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in May 2015. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData's proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

  • Analysis of the market trends for the pharmaceutical industry in the global arena.
  • Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
  • Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
  • Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
  • Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
  • Analysis of partnership and licensing deals based on clinical stage of development of products.
  • Summary of the pharmaceutical deals globally in the six months.
  • Information on the top deals happened in the pharmaceutical industry.
  • Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
  • League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

  • Enhance your decision making capability in a more rapid and time sensitive manner.
  • Find out the major deal performing segments for investments in your industry.
  • Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
  • Identify companies that are aggressively looking to raise capital in the market
  • Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
  • Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
  • Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
  • Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
  • Identify growth segments and opportunities in each region within the industry.
  • Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 5
  • 1.2 List of Figures 8

2 Pharmaceuticals & Healthcare, Global, Deal Summary 12

  • 2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, May 2015 12
  • 2.2 Pharmaceuticals & Healthcare, Global, Major Deals, May 2015 14
    • 2.2.1 AbbVie Raises USD16.7 Billion in Public Offering Notes 14
    • 2.2.2 Danaher to Acquire Pall for USD13.8 Billion 14
    • 2.2.3 Alexion Pharma to Acquire Synageva BioPharma for USD8.4 Billion 17
    • 2.2.4 Endo International to Acquire Par Pharma from TPG Capital for USD8.05 Billion 19
    • 2.2.5 Eli Lilly Prices Public Offering of Bonds for USD2.3 Billion 19
  • 2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, May 2015 20
  • 2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, May 2015 21

3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 22

  • 3.1 Pharmaceuticals & Healthcare, Global, M&A, May 2015 22
    • 3.1.1 Top M&A Deals in May 2015 23
    • 3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, December 2014 - May 2015 24
  • 3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, May 2015 26
    • 3.2.1 Top Equity Offering Deals in May 2015 27
    • 3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, December 2014 - May 2015 28
  • 3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, May 2015 30
    • 3.3.1 Top PE/VC Deals in May 2015 31
    • 3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, May 2015 32
    • 3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, May 2015 34
    • 3.3.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, December 2014-May 2015 36
    • 3.3.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, December 2014-May 2015 37

4 Pharmaceuticals & Healthcare, Global, Partnership Deals, May 2015 38

  • 4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, May 2015 38
  • 4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, December 2014 - May 2015 40
  • 4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), May 2015 42
    • 4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, May 2015 43
  • 4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), December 2014 - May 2015 44
  • 4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, December 2014 - May 2015 46
  • 4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), December 2014 - May 2015 47
  • 4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), December 2014 - May 2015 49

5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, May 2015 51

  • 5.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, May 2015 51
  • 5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), May 2015 53
  • 5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), December 2014 - May 2015 55
  • 5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), December 2014 - May 2015 57
  • 5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), December 2014 - May 2015 59
  • 5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), December 2014 - May 2015 62
    • 5.6.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, May 2015 63
    • 5.6.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, May 2015 64
    • 5.6.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, May 2015 64

6 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 65

  • 6.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, May 2015 65
    • 6.1.1 Oncology - Deals of the Month 66
  • 6.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, May 2015 68
    • 6.2.1 Central Nervous System - Deals of the Month 69
  • 6.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, May 2015 71
    • 6.3.1 Infectious Diseases - Deals of the Month 73
  • 6.4 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, May 2015 75
    • 6.4.1 Cardiovascular - Deals of the Month 77
  • 6.5 Pharmaceuticals & Healthcare, Global, Immunology Deals, May 2015 78
    • 6.5.1 Immunology - Deal of the Month 80
  • 6.6 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, May 2015 81
    • 6.6.1 Gastrointestinal - Deal of the Month 82
  • 6.7 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, May 2015 83
    • 6.7.1 Metabolic Disorders - Deal of the Month 84

7 Deal Summary by Geography 86

  • 7.1 Pharmaceuticals & Healthcare, North America Deals, May 2015 86
    • 7.1.1 North America - Deals of the Month 87
  • 7.2 Pharmaceuticals & Healthcare, Europe, Deals, May 2015 89
    • 7.2.1 Europe - Deals of the Month 91
  • 7.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, May 2015 93
    • 7.3.1 Asia-Pacific - Deals of the Month 94
  • 7.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, May 2015 96
    • 7.4.1 Rest of the World - Deals of the Month 97

8 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 98

  • 8.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, December 2014 - May 2015 98
  • 8.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, December 2014 - May 2015 100

9 Further Information 102

  • 9.1 Methodology 102
  • 9.2 About GlobalData 103
  • 9.3 Disclosure information 104
  • 9.4 Disclaimer 104

List of Tables

1.1 List of Tables

  • Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), December 2014 - May 2015 13
  • Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, May 2015 14
  • Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), May 2015 21
  • Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), December 2014 - May 2015 23
  • Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, May 2015 23
  • Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, December 2014 - May 2015 25
  • Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), December 2014 - May 2015 27
  • Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, May 2015 27
  • Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), December 2014 - May 2015 29
  • Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), December 2014 - May 2015 31
  • Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, May 2015 31
  • Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, December 2014 - May 2015 33
  • Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), May 2015 35
  • Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), December 2014 - May 2015 36
  • Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, December 2014 - May 2015 37
  • Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), December 2014 - May 2015 39
  • Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), December 2014 - May 2015 41
  • Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), December 2014 - May 2015 43
  • Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), May 2015 43
  • Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), December 2014 - May 2015 45
  • Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, December 2014 - May 2015 48
  • Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), December 2014 - May 2015 50
  • Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), December 2014 - May 2015 52
  • Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), December 2014 - May 2015 54
  • Table 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), December 2014 - May 2015 56
  • Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), May 2015 58
  • Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, December 2014 - May 2015 61
  • Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), May 2015 63
  • Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, May 2015 63
  • Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, May 2015 64
  • Table 31: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, May 2015 64
  • Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), December 2014 - May 2015 66
  • Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), December 2014 - May 2015 69
  • Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), December 2014 - May 2015 72
  • Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), December 2014 - May 2015 76
  • Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), December 2014 - May 2015 79
  • Table 37: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), December 2014 - May 2015 82
  • Table 38: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), December 2014 - May 2015 84
  • Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), December 2014 - May 2015 87
  • Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), December 2014 - May 2015 90
  • Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), December 2014 - May 2015 94
  • Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), December 2014 - May 2015 97
  • Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), December 2014 - May 2015 99
  • Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), December 2014 - May 2015 101

List of Figures

1.2 List of Figures

  • Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), December 2014 - May 2015 12
  • Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), May 2015 20
  • Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), May 2015 21
  • Figure 4: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), December 2014 - May 2015 22
  • Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, December 2014 - May 2015 24
  • Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), December 2014 - May 2015 26
  • Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), December 2014 - May 2015 28
  • Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), December 2014 - May 2015 30
  • Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, December 2014 - May 2015 32
  • Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), May 2015 34
  • Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), May 2015 35
  • Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), December 2014 - May 2015 36
  • Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), December 2014 - May 2015 38
  • Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), December 2014 - May 2015 40
  • Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), December 2014 - May 2015 42
  • Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), December 2014 - May 2015 44
  • Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, December 2014 - May 2015 46
  • Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, December 2014 - May 2015 47
  • Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), December 2014 - May 2015 49
  • Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), December 2014 - May 2015 51
  • Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), December 2014 - May 2015 53
  • Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), December 2014 - May 2015 55
  • Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), December 2014 - May 2015 57
  • Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, December 2014 - May 2015 59
  • Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), December 2014 - May 2015 60
  • Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), May 2015 62
  • Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), December 2014 - May 2015 65
  • Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), December 2014 - May 2015 68
  • Figure 29: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), December 2014 - May 2015 71
  • Figure 30: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), December 2014 - May 2015 75
  • Figure 31: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), December 2014 - May 2015 78
  • Figure 32: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), December 2014 - May 2015 81
  • Figure 33: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), December 2014 - May 2015 83
  • Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), December 2014 - May 2015 86
  • Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), December 2014 - May 2015 89
  • Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), December 2014 - May 2015 93
  • Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), December 2014 - May 2015 96
  • Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), December 2014 - May 2015 98
  • Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), December 2014 - May 2015 100
Show More
Pricing
  • Int'l: +1-860-674-8796
  • TollFree(US): +1-866-353-3335
  • Europe: +32-2-535-7543
  • Asia: +65-6223-2436
Back to Top